Jumpstart Foundry and GMDC partner on Health:Further – Retail Tomorrow event
NASHVILLE, Tenn., – Jumpstart Foundry and Global Market Development Center on Tuesday partnered to advance consumer health and wellness innovations through its Health:Further and Retail Tomorrow initiatives.
The partnership is expected to help fuel the growing movement from physician-centric to patient-centric care, where increasingly consumers are driving health care insurance choices, product purchases and wellness – a “health care = self care” model.
“We are excited about partnering with GMDC to explore new levels of health and wellness innovation and engagement for entrepreneurs,” stated Vic Gatto, CEO Jumpstart Foundry. “The industry is moving toward more patient-centric solutions and responsibility is being transferred from insurance companies and employers to consumers. There’s a migration of care out of the hospital and toward retailers, home settings and to patients.”
The first Health:Further – Retail Tomorrow partnership initiative will feature executives from Johnson & Johnson and Wakefern Food Corp. during the Health:Further 2016 conference Aug. 23-24 at the Music City Center in Nashville, Tenn.
Geoff Betrus, senior director of shopper solutions for Johnson & Johnson, and Chris Skyers, VP health and beauty care for Wakefern Food Corp. will reveal how the evolving health care landscape is driving consumer behavior – and how retailers are challenging manufacturers to think differently to impact a new shopping culture in the Affordable Care Act era.
“Now more than ever, the most important customer is the patient, who is empowered within the health care industry value chain. This shift is driving innovation downstream with the potential to generate immense and consistent sales and profit growth at the retail level,” commented Patrick Spear, president and CEO of GMDC. “With our new Jumpstart Foundry partnership, we will advance an innovative Health:Further – Retail Tomorrow culture, where health care is transforming into self care.”
GMDC is an official supporting organization of Health:Further and as a result, members receive a 35% discount to attend.
In an uncertain health care atmosphere and average consumer costs increasing 20% year-over-year, Health:Further recognizes a need for innovation that drives opportunity in the industry. The Nashville-based conference series seeks to bring established retailers and suppliers to the same table as innovators and investors to foster the conversations that are moving health care forward.
In its first year, Health:Further attracted more than 600 attendees for a sold out crowd at the OMNI Nashville Hotel. The program featured C-level speakers from major healthcare companies like HCA and Saint Thomas Health as well as pitches from some of the most innovative emerging health care companies. The 2016 Health:Further Summit will build on this success to fill the Music City Center with more than 1,000 attendees targeting health care industry executives, entrepreneurs, investors and Fortune 500 companies.
In addition to programming, Health:Further 2016 will feature new experiences, including investor matchmaking and mentor hours.
CHPA, FDA discussing user fee program for OTC drugs
WASHINGTON — Since the Food and Drug Administration’s March 25, 2014 Part 15 public hearing on the OTC Drug Monograph, the Consumer Healthcare Products Association has been in discussions with FDA and relevant committees in Congress to identify potential enhancements that would update and modernize this regulatory framework for most nonprescription medicines.
"CHPA strongly supports the OTC Monograph System, but we believe that policy reforms could make the system more flexible, responsive and accommodating to innovation," the association noted in a press release issued Tuesday. "We recognize that resource constraints would affect the ability of FDA to implement any potential monograph reforms, and we are open to discussing ways of adequately funding reforms, including consideration of a user fee program for OTC drugs."
Following the FDA Public Meeting on OTC Monograph User Fees on June 10, 2016, CHPA has entered the stage of discussion that will include detailed talks about the parameters of a potential user fee framework.
Any such framework would require Congressional action. The FDA will post public minutes of these meetings on its website.
Protein Sciences: FDA approves 2016/17 formulation of Flublok
MERIDEN, Conn. – Protein Sciences Corporation on Tuesday announced that FDA has approved the 2016/17 formulation of Flublok influenza vaccine.
FDA approval of the 2016/17 formulation of Flublok means that Flublok is on track to ship to healthcare providers in early August.
"The timing of this approval could not be better. We will be able distribute Flublok earlier this season than before," stated Manon Cox, president and CEO of Protein Sciences Corporation. "In a surprise turn of events, CDC recently recommended against the use of FluMist vaccine that will result in a significant shortage of flu vaccines this season. Flublok is an excellent alternative for adults 18 and older."
This year FDA mandated two new components be made for trivalent flu vaccines, including a new H3N2 component that is also required for quadrivalent vaccines.
In a post-marketing clinical study of 9,000 adults 50 years and older during the 2014/15 flu season where H3N2 influenza was dominant, people who received Flublok were over 40% less likely to get cell culture confirmed influenza than people who received an egg-based flu vaccine, Protein Sciences reported.